CRO Group Picks Seven US Sites To Reap Big Gains In Trial Diversity

The Association of Clinical Research Organizations has awarded “seed funding” to seven US-based community clinical trial sites to demonstrate proof-of-concept projects aimed at increasing diversity in clinical trials.

Closeup of a support hands. Closeup shot of a young woman holding a senior man's hands in comfort. Female carer holding hands of senior man
Leveraging Community Knowledge And Relationships Can Enhance Clinical Trial Diversity (Shutterstock)

Seven US-based clinical trial sites with innovative ideas to improve diversity and inclusion in their studies, through measures such as better outreach and training, have received grants from the Association of Clinical Research Organizations, which represents global clinical research and technology organizations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Diversity & Inclusion

Makary Signals Some Interest In US FDA Staff Cuts, Fighting Patent Thickets

 

The FDA Commissioner nominee also commented on trial diversity, the role of public comment and expedited biosimilar reviews during his Senate confirmation hearing.

US FDA Says Restored Webpages Do Not Reflect ‘Biological Reality’

 
• By 

Clinical trial draft guidance webpages are back online following a court order, but with new language disclaiming any information promoting gender ideology as "extremely inaccurate."

CRO Group Picks Seven US Sites To Reap Big Gains In Trial Diversity

 
• By 

The Association of Clinical Research Organizations has awarded “seed funding” to seven US-based community clinical trial sites to demonstrate proof-of-concept projects aimed at increasing diversity in clinical trials.

Kennedy Would Issue Trial Diversity Guidance, But Not Necessarily Roll Back All Anti-DEI Actions

 

The US Health and Human Services Secretary nominee’s commitment should be a positive sign for those who want to ensure Americans can access adequate data on drugs in all populations that could use them.

More from Geography